Speakers
-
Richard Bergström IQVIARichard BergströmRichard Bergström
Former EFPIA Director Genera
European Health Policy: what is Brussel up to?
I will talk about new proposed EU legislation on secondary use of data (European Health Data Space and the AI Act). I will also cover the pharma package where the final proposal is expected during the spring. I will also reflect on the role of HTA going forward and finally on the relationship CH-EU.
Bio
Richard Bergström is a pharmacist by training. He received his MScPharm degree from the University of Uppsala, Sweden in 1988 and his honorary doctor title in October 2022. For 10 years he worked in regulatory affairs at global and EU level at Roche and Novartis. For 15 years he was a lobbyist for pharma leading the industry association in Sweden and the in Brussels. During the pandemic he was the vaccine coordinator for the Swedish government and part of the EU Joint Negotation Team. In September 2022 he joined IQVIA as Vice President European Affairs based in Rotkreuz. He is also a member of the Board of European Health Forum Gastein. -
Cécile Dussart Independent Board Member and Chair of the ESG committee at EuroAPICécile DussartCécile Dussart
Independent Board Member and Chair of the ESG committee at EuroAPI
Current trends in life science/pharmaceutical industry supply chain....
Are changes accelerating in manufacturing?
In this presentation we will focus on the main developments observed are in the Pharma industry manufacturing specifically from geopolitical, commercial social and environmental standpoints.
We will focus on evolution of those areas the recent past, present time and in years to come
What is the magnitude of changes in those areas?
What are their likely impacts on the Pharma landscape in years to comeHow are Pharma players adapting to changes occurring? responding to those? triggering those? Following those?
Practical illustrations, experiences from some main players on markets will be shared.
How much are different players likely or prepared to invest in those changes?
Finally What value will come out of those changes for Pharma players and patients?
Bio
Cécile Dussart is a successful C-Suite Business leader with 30 years’ working for iconic multinationals in the consumer care, pharmaceutical and medical device industries: Sanofi, Roche, and Galderma, with expertise and experience in business, technical operations and ESG. Experienced working in different environments with various stakeholders and governance models, including joint venture, wholly owned subsidiary and private equity. Cécile has a track record of driving customer-focused innovation and transformation, and of building high-performing teams and positive culture dynamics.
At Galderma , Cécile was serving as Head of Operations and ESG. Member of the Executive Committee, she was leading the strategic agenda ,scaling up the new organization and digital capabilities, transforming the manufacturing facilities for success. She was driving fro Global Supply Chain Quality and Procurement the implementation of the business process outsourcing while managing a double-digit growth in a very volatile environment. Board experience. Independent Board Member at EuroAPI, Chair of the ESG Committee at EuroAPI,and Member of the Advisory Committee at Neobrain. -
Chris Easton Johnson & JohnsonChris EastonChris Easton
Disease Area Stronghold Global Commercial Leader, Pulmonary Hypertension, Johnson & Johnson (Janssen Pharmaceuticals)
Bio
Chris Easton is a Senior Leader and Global Commercial Franchise Head for Pulmonary Hypertension at Janssen Pharmaceuticals [part of Johnson & Johnson] in Basel; where he leads multiple Global Strategic functions including Marketing, Early Asset Development & Digital Acceleration. He is also the Co-Chair with R&D for the Disease Area Stronghold to ensure all opportunities to transform the treatment paradigm in Pulmonary Hypertension are addressed. Chris has also undertaken numerous international key notes, round table & panel positions, and advisory roles where he shared his passion for transforming patient outcomes and SICKcare to HEALTHcare. He is also a visiting professor at the Lisbon School of Economics & Management, where he gives a lecture titled Mission: Patient Centricity. -
Brian Finrow Lumen BioscienceBrian FinrowBrian Finrow
CEO and co-founder of Lumen Bioscience
The sustainability of biopharma R&D productivity: Is 2023 the "perfect storm"?
TBD
Bio
TBD -
Neil Grubert Independent ConsultantNeil GrubertNeil Grubert
Independent Global Market Access Consultant, Trainer and Writer
Market access: moving from an adversarial to a collaborative relationship with healthcare systems
The pricing relationship between healthcare systems and pharma has all too often been adversarial in nature, but there is now a need for a more collaborative approach. Unusually, emerging markets may offer some lessons for mature markets: companies have long worked individually with healthcare systems and are now forming international coalitions to expedite access. Pharma also has a long tradition of collaboration with academia and is now forging international alliances in fields such as real-world evidence. Governments in Europe are looking to attract investment from life sciences companies, presenting opportunities to reshape the relationship. The UK has gone further than most countries in creating a complete ecosystem for rapid access, though major challenges remain in relation to cost-containment policy. This presentation will explore these themes using specific examples of industry partnerships.
Bio
Neil Grubert has more than 20 years’ experience in pricing, reimbursement, and market access. He spearheaded the development of Decision Resources Group’s international market access business, most recently as Vice President of Global Market Access Insights. Since 2014, he has been working as an independent market access consultant, trainer, and writer. His daily posts on global access issues have gained a wide following on LinkedIn, and he is a regular speaker at industry events and company in-house meetings. -
Lutz Hegemann Novartis AGLutz HegemannLutz Hegemann
President Global Health & Sustainability at Novartis
Sustainability in the biopharma industry: how partnerships can drive impact
Despite tangible improvements in human health outcomes over the last three decades, fundamental challenges remain in the field of healthcare. In a fragmented post-pandemic world, the biopharma industry faces the strain of ageing populations, over-stretched health systems and notably, the growing dual burden of communicable and non-communicable diseases in low-to-middle income countries. These health challenges are coupled with the rising societal demand for sustainability across different healthcare business practices and dimensions. Dr. Lutz Hegemann will provide an overview on what biopharma sustainability looks like, including the areas in which pharmaceutical companies can create the greatest impact, and the pivotal role that partnerships can play in driving this.
Bio
Lutz Hegemann leads the Novartis Global Health unit and is responsible for integrating environmental, social and governance (ESG) matters into the core of the company’s business, with a special emphasis on innovation and access.
Before taking on his present role, Lutz was Group Head of Corporate Affairs and Global Health. He has held roles of increasing responsibility since joining Novartis in 2005 in the Consumer Health Division. He began his career as a public health physician and scientist.
Lutz is a Fellow of the Royal Society for Tropical Medicine & Hygiene and serves on the boards of the Novartis Foundation, the Swiss Alliance against Neglected Tropical Diseases, the Tanzania Training Centre of International Health, PATH, and the Swiss Tropical and Public Health Institute. -
Lelio Marmora Management LabLelio MarmoraLelio Marmora
CEO at The Management Lab
The Global Fight against the Big Pandemics: A case study on Partnerships, Sustainability and Innovation
The global response against HIV-Aids, Tuberculosis and Malaria has shown remarkable progress over the last two decades. Concerted efforts between international partners, Governments, Private Sector and Civil Society, have allowed unprecedented investments, saving millions of lives and introducing new treatments, diagnostics and medical devices to the market.
Despite the disruptions caused by the COVID-19 and other challenges likeAntimicrobial Resistance and competing funding priorities, the world is getting back on track towards ending the big pandemics.
How can the global fight continue progressing and innovating? What strategic elements could be adjusted to collaborate more efficiently, and to enhance the market's opportunities? In this session I will discuss the success factors and potential areas of optimization to raise the partners’ game, with a specific focus on the role of the Industry.
Bio
Lelio Marmora is an international development leader with more than 30 years of experience overseeing public and private large-scale investments in more than 120 countries. He served as Executive Director of Unitaid in Geneva, Switzerland, from 2014 to 2020, overseeing a $2B portfolio of investments in global health innovation. Prior to that, he worked 8 years at the Global Fund to Fight AIDS, TB and Malaria, first in charge of the Latin America and the Caribbean region, and then as Director for Africa and the Middle East ($8+B portfolios). Earlier in his career, Lelio served in various capacities at a range of international organizations, including the World Bank, the Inter American Development Bank and several United Nations agencies. Lelio is the CEO of The Management Lab, a consulting firm based in Geneva, Switzerland, specialized in international development public/private large-scale investments. He also servesas a member of the Board of Directors at Orasure Technologies Inc. (NASDAQ: OSUR), aBoard Member of the MTV Foundation, and is also a founding member of the Think Tank Santé Mondiale 2030 in Paris, France.Lelio is the recipient of several national Orders and national/international awards. Alma Mater: Université Panthéon-Assas (Paris II) - Paris, France -
Anne Njis RocheAnne NjisAnne Njis
Transformation Lead Rare Conditions at Roche
The mindset of partnering to create sustainability: a necessary shift to shape a sustainable Health Care.
How does that translate in the way pharma companies develop innovation, and bring this innovation to patients in the current and future healthcare ecosystem...
The infinity model aims to achieve what company leaders see as a 'triple' win in value creation - creating value for patients, for society, and for the company. A true customer-centric approach that Roche was leading to make a difference in rare diseases and even beyond. A conversation with Anne Nijs about the mindset shifts as well as the pitfalls from a real practitioner.
Reference: Mc Kinsey articles: Roche's Infinity Model: Helping to transform the lives of patients with rare diseases July 2021, Developing a customer -centric approach to rare conditions, McKinsey October 22.
Bio
Anne has an accomplished 30+ year career in the pharmaceutical industry, spanning managing director and vice president roles across top global organisations. Her leadership ethos is deeply influenced by the idea of giving away power rather than hoarding it, to multiply creativity, deepen trust and grow inclusivity – and so enable the emergence of new organisational orders. As a senior leader operating in both developed and emerging markets, Anne is highly skilled at navigating large, complex organisations to deliver lasting change. Her experience in operating in ambiguous and dynamic healthcare systems necessitates dexterity of thinking, adaptability, and determination to see change realised. Anne is a published expert in customer-centric transformation and prior member of the Greek, Ukrainian and the Argentinian Pharma Associations. She is a global citizen, speaks six languages and has lived in eight countries. -
Michael Oberreiter RocheMichael OberreiterMichael Oberreiter
Head of Global Access at Roche
Emerging from Disruption: Rethinking Pharma
Healthcare has faded from the global agenda very quickly. Covid-19 is seemingly a thing of the past. The global cost of over $12 trillion US dollar till the end of 2024 caused by the pandemic is almost forgotten and is now just a precursor to a world of inflation, war and energy shortages. For healthcare systems, this means not only a shift of focus away from health, but acute economic headwinds putting even more pressure on budgets. This means for the healthcare industry an increasing pressure to demonstrate the benefit of sustainable investments in health and the broader societal value of investing in innovative medicines and solutions. But not all is doom and gloom. There are enormous opportunities coming from the acceleration and combination of data and digitalisation to bring public health level solutions that are better for patients and more cost effective for healthcare systems. There is an openness to private sector partnership like never before - primarily as a result of Covid and a recognition that healthcare needs the private sector - but also from the entrance of new players with the data and digital expertise the public sector does not have. The advance of new technologies and discoveries - as well as innovative combinations of existing ones - have the potential to fundamentally change the way we prevent, diagnose and treat diseases and by doing that significantly contribute to sustainability goals.
Bio
Michael Oberreiter is Head of Global Access at Roche, based in Basel. He is an economist by training and completed a post-graduate diploma and master studies in International Politics and Communications. Michael has been involved in the field of health policy, patient access, capacity building and health economics for over 25 years. His experience spans across different therapeutic areas, countries – including Austria, Germany, China and Asia Pacific (APAC) where he was responsible for driving the development of sustainable Policy, Access and System Capacity solutions to strengthen the Healthcare system and improve access to innovative treatments. -
Bentinck Oswald Rocket Pharmaceuticals, Inc.Bentinck OswaldOswald Bentinck
VP, Global Head - Value and Access at Rocket Pharmaceuticals
The promise of cell & gene therapies – is the European healthcare system equipped to fairly value and pay for one-time, potentially curative treatments
The healthcare industry is at an inflection point with the market now preparing for many cell and gene therapies to be approved over the coming years. A handful of these therapies have been approved to date and are gaining reimbursement whereas others have failed to gain access. What has driven the success and failure of these various cell & gene therapies and what will need to change to ensure sustained investment in research and development of these highly innovative, yet complex therapies? Systems are currently designed to value and pay for chronic and conventional therapies. New innovative outcomes-based and payment approaches are needed, combined with clear guidelines on real-world evidence requirements, to ensure uncertainties about durability of effect and cost can be addressed. Some of the reasons for successes and failures to date, as well as some potential solutions to overcome current barriers to access will be reflected upon.
Bio
Oswald currently serves as Global Head of Value and Access at Rocket Pharmaceuticals, a clinical-stage biotech, advancing an integrated pipeline of LVV & AAV genetic therapies that correct the root cause of complex and rare life-threatening childhood hematological disorders and cardiomyopathies. He joined Rocket in August 2022. Before Rocket, Oswald was Head of Value and Access EMEA at AveXis/Novartis Gene Therapies that successfully launched Zolgensma, a gene therapy for spinal muscular atrophy (SMA). Earlier Oswald worked in various regional and global marketing and market access roles at Pfizer, Shire, and Alexion. He has 20 years’ commercial experience in the pharmaceutical industry with over 10 of those focusing on rare diseases. He holds an LLM in Tax Law from the University of Amsterdam and an MSc in Health Economics, Policy and Management from The London School of Economics and Political Science (LSE). -
Jean Vielle Novartis AGJean VielleJean Vielle
Global Head Integration Separation, Novartis AG
Current trends in life science/pharmaceutical industry supply chain....
Are changes accelerating in manufacturing?
In this presentation we will focus on the main developments observed are in the Pharma industry manufacturing specifically from geopolitical, commercial social and environmental standpoints.- We will focus on evolution of those areas the recent past, present time and in years to come
- What is the magnitude of changes in those areas?
- What are their likely impacts on the Pharma landscape in years to come
How are Pharma players adapting to changes occurring? responding to those? triggering those? Following those?
Practical illustrations, experiences from some main players on markets will be shared.
How much are different players likely or prepared to invest in those changes?
Finally What value will come out of those changes for Pharma players and patients?
Bio
Jean Vielle is Global Head Integration/Separation at Novartis Pharma AG Roche based in Basel, Switzerland. In this role, he has responsibility for structuring and negotiating acquisition and sale agreements for assets and technologies. At Novartis for 21 years Jean started prior to his current role in technical Project management to then work on divestments, Pharma Operations strategy, Procurement, CMO management. Jean joined Novartis from major chemical and consulting companies. He graduated in science and then studied in business and administration as well. -
Susanne Weissbäcker Partner EY-ParthenonSusanne WeissbäckerSusanne Weissbäcker
Partner EY-Parthenon, Strategy Life Sciences
Bio
Susanne is a partner in the Health, Sciences and Wellness sector at EY-Parthenon since August 2021. Reflecting her broad experience, Susanne is focusing on supporting life sciences clients on strategy, strategic partnering, broader access and value, and sustainability. She has deep expertise and a strong personal belief in partnering to build partner ecosystems, offering mutual value to established organizations and start-ups.
Susanne is also co-leading EY-Parthenon Strategy in Switzerland.
As a physician by education and training and with a degree in business, Susanne has ~20 years of experience working in global health and life sciences. Before joining EY-Parthenon, Susanne worked for Takeda as Global Head of Access to Medicines, a member of the Growth & Emerging Markets Leadership team, based in Singapore and prior that as Head of Patient Services & Trade in Europe & Canada. Prior joining the industry, Susanne led the Business Health and Healthcare Community at the World Economic Forum, driving thought leadership on value-based healthcare while working with CEOs and partners across all sectors. Susanne started her career in consulting in Europe and the Middle East. -
Andy Wilkins FUTURE OF HEALTHAndy WilkinsAndy Wilkins
Founder, FUTURE OF HEALTH
The Future of Healthcare in the 21st Century
TBD
Bio
TBD